- Caixa Capital Risc has rebranded as Criteria Capital Risc as its parent company, CriteriaCaixa, prepares to invest €300 million in early-stage biotechnology, healthcare, and technology companies through 2030.
- The investment program is part of CriteriaCaixa’s 2030 Strategic Plan and will be executed through two specialized funds: Criteria Bio Ventures and Criteria Venture Tech.
- Investments will primarily target companies in Spain and Portugal, with selective opportunities also considered across Europe and North America.
- Criteria Capital Risc has operated as an active investor in the Iberian venture capital market for more than two decades.
- Through its specialized investment vehicles, Criteria Capital Risc takes an active role in supporting portfolio companies.
- CriteriaCaixa reported a gross asset value of approximately €45 billion in 2025.
- Criteria Capital Risc’s €300 million investment plan will give the firm greater capacity to support companies through multiple stages of growth.
- Under the 2030 Strategic Plan, the combined gross asset value of Criteria Capital Risc, Criteria PE Management, and InmoCaixa will be limited to 10% of CriteriaCaixa’s total gross asset value.
- Approximately 70% of the current venture portfolio’s value is represented by investments in Spain, reflecting CriteriaCaixa’s commitment to supporting the country’s startup, scientific, and innovation ecosystem.
- Criteria Venture Tech concentrates on deep technology and several strategically important markets, including artificial intelligence, cybersecurity, software, and data infrastructure.
- Barcelona, Spain-based CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, today announces a reboot of its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies.
- Through its two funds, Criteria Bio Ventures and Criteria Venture Tech, it plans to invest €300 million in innovative early-stage companies, to promote transformative therapies and technologies that can have a positive impact on society, prioritizing long-term value creation.
Caixa Capital Risc has officially rebranded as Criteria Capital Risc, aligning with its parent company, CriteriaCaixa, which aims to invest €300 million in early-stage companies by 2030. This investment strategy is part of the 2030 Strategic Plan and will be executed through two specialized funds: Criteria Bio Ventures and Criteria Venture Tech.1245681012
The focus will be on sectors such as biotechnology, healthcare, and technology, primarily targeting companies in Spain and Portugal, while also considering opportunities across Europe and North America. Approximately 70% of the current venture portfolio’s value is invested in Spain, underscoring CriteriaCaixa’s commitment to enhancing the country’s startup ecosystem.39
Criteria Capital Risc has been an active player in the Iberian venture capital market for over two decades, supporting portfolio companies through its specialized investment vehicles. The Criteria Venture Tech fund will focus on deep technology sectors, including artificial intelligence, cybersecurity, software, and data infrastructure.
In 2025, CriteriaCaixa reported a gross asset value of approximately €45 billion, with the combined gross asset value of Criteria Capital Risc, Criteria PE Management, and InmoCaixa capped at 10% of the total gross asset value under the strategic plan.
“The €300 million program will be deployed through two specialized funds—Criteria Bio Ventures and Criteria Venture Tech—concentrating on biotech and deep technology sectors such as AI and cybersecurity. Criteria Capital Risc has operated as an active investor in the Iberian venture capital market for more than two decades, with about 70% of its current portfolio value in Spain.”
Pulse 2.0
